Targeting metabolic disturbance in the diabetic heart

Cardiovasc Diabetol. 2015 Feb 7:14:17. doi: 10.1186/s12933-015-0173-8.

Abstract

Diabetic cardiomyopathy is defined as ventricular dysfunction initiated by alterations in cardiac energy substrates in the absence of coronary artery disease and hypertension. In addition to the demonstrated burden of cardiovascular events associated with diabetes, diabetic cardiomyopathy partly explains why diabetic patients are subject to a greater risk of heart failure and a worse outcome after myocardial ischemia. The raising prevalence and accumulating costs of cardiovascular disease in diabetic patients underscore the deficiencies of tertiary prevention and call for a shift in medical treatment. It is becoming increasingly clearer that the effective prevention and treatment of diabetic cardiomyopathy require measures to regulate the metabolic derangement occurring in the heart rather than merely restoring suitable systemic parameters. Recent research has provided deeper insight into the metabolic etiology of diabetic cardiomyopathy and numerous heart-specific targets that may substitute or reinforce current strategies. From both experimental and translational perspectives, in this review we first discuss the progress made with conventional therapies, and then focus on the need for prospective metabolic targets that may avert myocardial vulnerability and functional decline in next-generation diabetic care.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Diabetes Mellitus / drug therapy
  • Diabetes Mellitus / epidemiology
  • Diabetes Mellitus / metabolism*
  • Diabetic Cardiomyopathies / drug therapy
  • Diabetic Cardiomyopathies / epidemiology
  • Diabetic Cardiomyopathies / metabolism*
  • Drug Delivery Systems / trends
  • Humans
  • Metabolic Diseases / drug therapy
  • Metabolic Diseases / epidemiology
  • Metabolic Diseases / metabolism*